



**\$125 Million**  
Follow-On Offering

**svb** Securities  
Joint Bookrunner  
January 2023

## SVB Securities Serves as Joint Bookrunner for Fulcrum Therapeutics' (Nasdaq: FULC) \$125 Million Follow-On Offering

### Key Transaction Highlights

- Confidentially launched January 17th, publicly launched January 17th post-close and priced overnight
- Well oversubscribed from both new and existing investors
- Base deal was upsized from \$100 million to \$125 million.
- Base deal consisted of 9,615,384 shares at a price of \$13.00 per share, representing a 5.1% discount from launch.
- Fulcrum intends to use the net proceeds from this offering primarily for general corporate purposes, which may include working capital and capital expenditures, research and development expenses, including to fund clinical trials, regulatory submissions, commercialization, discovery and additional preclinical research and development of additional product candidates and platform enhancement, general and administrative expenses, and potential acquisitions of, or investments in, companies, technologies, products or assets that complement its business.
- Transaction represents SVB Securities' 6th equity transaction for Fulcrum, having previously served as joint bookrunner on its July 2019 initial public offering, exclusive placement agent on its June 2020 PIPE offering, lead-left bookrunner on its January 2021 and August 2021 follow-on offerings and as joint bookrunner on its August 2022 follow-on offering.
- This is SVB Securities' 1st bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**  
53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

**NASHVILLE**  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**  
255 California Street  
12th Floor  
San Francisco, CA 94111